The effect of drug dose and drug exposure time on the binding, internalization, and cytotoxicity of radiolabeled somatostatin analogs

被引:7
作者
Anthony, CT
Hughey, S
Lyons, J
Weiss, S
Hornick, CA
Drouant, GJ
Fuselier, JA
Coy, DH
Murphy, WA
Woltering, EA
机构
[1] Louisiana State Univ, Hlth Sci Ctr, Dept Surg, New Orleans, LA 70112 USA
[2] Louisiana State Univ, Hlth Sci Ctr, Dept Physiol, New Orleans, LA 70112 USA
[3] Tulane Univ, Peptide Res Lab, New Orleans, LA 70118 USA
[4] Louisiana State Univ, Hlth Sci Ctr, Stanley S Scott Canc Ctr, New Orleans, LA 70112 USA
[5] Louisiana State Univ, Hlth Sci Ctr, Neurosci Ctr Excellence, New Orleans, LA 70112 USA
[6] Vet Affairs Med Ctr, New Orleans, LA 70146 USA
关键词
somatostatin; membrane binding; internalization; cytotoxicity; irradiation;
D O I
10.1016/j.jss.2003.06.002
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background. Creation of protease-resistant somatostatin analogs has allowed development of these peptides as clinically useful drugs. Widespread diagnostic use of radiolabeled somatostatin analogs has enhanced interest in the binding and intracellular distribution of these peptides. The degree of drug internalization and length of drug retention may be critical for drug-induced cytotoxicity. We hypothesized that the ability of a radiolabeled peptide to bind to a cell, be internalized, and induce cytotoxicity is proportional to both the radioligand concentration and the exposure time. Materials and methods. To test this hypothesis, somatostatin receptor-expressing cells (IMR-32) were incubated with In-111-pentetreotide, a sst 2 preferring somatostatin analogue. Radioligand exposure time and/or concentration were varied. Results. Prolonged exposure to a fixed concentration of radioligand resulted in progressive increases in whole cell binding and internalization over time. Cells exposed to a relatively fixed number of muCi-Hr yielded constant whole cell binding and internalization. Increasing the muCi-Hr resulted in a proportionate increase in binding. Cytotoxicity was also proportional to the dose of radiation regardless of whether the exposure was internalized radiation (muCi-Hr from (111)Inpentetreotide) or from external beam radiation (cGy). Conclusion. Both drug exposure time and drug concentration contribute to cell binding and cytotoxicity in this model and their relative contributions are inversely related. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:1 / 13
页数:13
相关论文
共 24 条
[1]   Experiences with high dose radiopeptide therapy: The health physics perspective [J].
Espenan, GD ;
Nelson, JA ;
Fisher, DR ;
Diaco, DS ;
McCarthy, KE ;
Anthony, LB ;
Maloney, TJ ;
Woltering, EA .
HEALTH PHYSICS, 1999, 76 (03) :225-235
[2]  
Gulec SA, 2001, AM SURGEON, V67, P1068
[3]   Antitumor and antiangiogenic effects of somatostatin receptor-targeted in situ radiation with 111In-DTPA-JIC 2DL [J].
Gulec, SA ;
Drouant, GJ ;
Fuselier, J ;
Anthony, CT ;
Heneghan, J ;
DelCarpio, JB ;
Coy, DH ;
Murphy, WA ;
Woltering, EA .
JOURNAL OF SURGICAL RESEARCH, 2001, 97 (02) :131-137
[4]   Protein kinase C activation stimulates the phosphorylation and internalization of the sst2A somatostatin receptor [J].
Hipkin, RW ;
Wang, YN ;
Schonbrunn, A .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (08) :5591-5599
[5]   Agonist-induced desensitization, internalization, and phosphorylation of the sst2A somatostatin receptor [J].
Hipkin, RW ;
Friedman, J ;
Clark, RB ;
Eppler, CM ;
Schonbrunn, A .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (21) :13869-13876
[6]   DISSOCIATION OF ANTIPROLIFERATIVE AND ANTIHORMONAL EFFECTS OF THE SOMATOSTATIN ANALOG OCTREOTIDE ON 7315B PITUITARY-TUMOR CELLS [J].
HOFLAND, LJ ;
VANKOETSVELD, PM ;
WOUTERS, N ;
WAAIJERS, M ;
REUBI, JC ;
LAMBERTS, SWJ .
ENDOCRINOLOGY, 1992, 131 (02) :571-577
[7]   INTERNALIZATION OF THE RADIOIODINATED SOMATOSTATIN ANALOG [I-125-TYR(3)]OCTREOTIDE BY MOUSE AND HUMAN PITUITARY-TUMOR CELLS - INCREASE BY UNLABELED OCTREOTIDE [J].
HOFLAND, LJ ;
VANKOETSVELD, PM ;
WAAIJERS, M ;
ZUYDERWIJK, J ;
BREEMAN, WAP ;
LAMBERTS, SWJ .
ENDOCRINOLOGY, 1995, 136 (09) :3698-3706
[8]  
Hornick CA, 2000, J NUCL MED, V41, P1256
[9]  
Janson ET, 2000, J NUCL MED, V41, P1514
[10]  
Karamychev VN, 2000, J NUCL MED, V41, P1093